TITLE

P-selectin in Major Depression: Preliminary Findings with Venlafaxine Treatment

AUTHOR(S)
Piletz, John E.; Halaris, Angelos; Iqbal, Omer; Hoppensteadt, Debra; Fareed, Jawed; Zhu, He; Sinacore, James; DeVane, C. Lindsay
PUB. DATE
April 2010
SOURCE
International Journal of Health Science;Apr-Jun2010, Vol. 3 Issue 2, p312
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background Disturbances in affective state are known to cause platelet activation, which may relate to evidence linking major depression and coronary artery disease. The platelet activation biomarker, P-selectin, exists in various blood fractions that demarcate steps of platelet activation. If circulating platelets are more activated in depressed patients, the literature suggests that amongst antidepressant classes, the Serotonin- Selective Reuptake Inhibitors (SSRIs) are best able to normalize this abnormality. Serotonin/ Norepinephrine Reuptake Inhibitors (SNRIs), like venlafaxine, have not been studied in this regard. Aim of the Study To determine the status of activated P-selectin (platelet surface- bound and/or released forms) in depressed patients before and after 8 weeks of treatment with the SNRI, venlafaxine. Methods Baseline (untreated) subjects were major depressives (n= 23) and age/sex-matched healthy controls (n= 17) with no evidence of coronary artery disease. A subgroup of the depressed cohort (n= 15) was restudied after 4 and 8 weeks on venlafaxine. P-selectin levels were compared to two biomarkers not known to change during platelet activation: the membranous fibronectin-signaling protein, IRAS, and the antigen of the GPIIb/IIIa receptor, CD61. Results At baseline, both activated forms of P-Selectin were high in the depressives, but only the soluble form showed statistical significance (p= 0.03) versus healthy controls. Venlafaxine treatment led to mood normalization based on reduced Hamilton Depression scores (p< 0.0001), while the level of soluble P-selectin was non-significantly lowered (p= 0.13). Platelet membranous IRAS and CD61 levels were normal at baseline but down-regulated after 4 and 8 weeks of treatment (p = 0.01 each). Conclusion High levels of soluble P-selectin were identified in depression, indicative of platelet activation. Venlafaxine treatment had minimal effect on soluble P-selectin but had clear effects on platelet IRAS and CD61. Therefore, platelet activation does not readily normalize with mood correction after 8 weeks on venlafaxine, but other platelet effects seem to occur.
ACCESSION #
56562976

 

Related Articles

  • Nanotechnology and Atherosclerosis Imaging: Emerging Diagnostic and Therapeutic Applications. Schoenhagen, Paul; Conyers, Jodie L. // Recent Patents on Cardiovascular Drug Discovery;Jun2008, Vol. 3 Issue 2, p98 

    Despite enormous therapeutic advances, coronary artery disease (CAD) remains a global public health problem. Effective prevention of cardiovascular morbidity and mortality will require the development of new diagnostic and therapeutic strategies aimed at treating early, subclinical disease...

  • Curbing Inflammation in the Ischemic Heart Disease. Evora, Paulo Roberto B.; Nather, Julio; Tubino, Paulo Victor; Albuquerque, Agnes Afrodite S.; Celotto, Andrea Carla; Rodrigues, Alfredo J. // International Journal of Inflammation;2013, p1 

    A modern concept considers acute coronary syndrome as an autoinflammatory disorder. From the onset to the healing stage, an endless inflammation has been presented with complex, multiple cross-talk mechanisms at the molecular, cellular, and organ levels. Inflammatory response following acute...

  • Biochemical cardiac markers: Present and future. Christenson, Robert H. // MLO: Medical Laboratory Observer;Sep99, Vol. 31 Issue 9, p26 

    Presents the important role for diagnosis and guide to preventive therapy for myocardial infarction and ischemia in the U.S. Characteristics of the traditional biochemical markers of myocardial infarction (MI); Benchmark for the diagnosis of MI; Evaluation of cardiac marker utilization.

  • Relation between C reactive protein and depression remission status in patients presenting with acute coronary syndrome. Shimbo, D.; Rieckmann, N.; Paulino, R.; Davidson, K. W. // Heart;Sep2006, Vol. 92 Issue 9, p1316 

    The article examines the relation between the course of depression and C reactive protein (CRP) concentrations after an acute coronary syndrome. Patients were enrolled from an ancillary study of Coronary Psychosocial Patient Evaluation Study. No significant differences were found in CRP...

  • Depression as a non-causal variable risk marker in coronary heart disease. Meijer, Anna; Zuidersma, Marij; De Jonge, Peter // BMC Medicine;2013, Vol. 11 Issue 1, p1 

    Background: After decades of investigations, explanations for the prospective association between depression and coronary heart disease (CHD) are still incomplete. Discussion: Depression is often suggested to be causally related to CHD. Based on the available literature, we would rather argue...

  • Evaluating the causal relevance of diverse risk markers: horizontal systematic review. Kuper, Hannah; Nicholson, Amanda; Kivimaki, Mika; Aitsi-Selmi, Amina; Cavalleri, Gianpiero; Deanfield, John E.; Heuschmann, Peter; Jouven, Xavier; Malyutina, Sofia; Mayosi, Bongani M.; Sans, Susanna; Thomsen, Troels; Witteman, Jacqueline C. M.; Hingorani, Aroon D.; Lawlor, Debbie A.; Hemingway, Harry // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;11/28/2009, Vol. 339 Issue 7732, p1240 

    The article offers information on a study which determined the most robust method for systemically reviewing evidence on a full range of risk markers for coronary heart disease. Identified risk markers are depression, exercise and C reactive proteins, among others. Primary outcomes included...

  • Platelet activating factors are associated with depressive symptoms in coronary artery disease patients: a hypothesis-generating study. Mazereeuw, Graham; Herrmann, Nathan; Hongbin Xu; Blanchard, Alexandre P.; Figeys, Daniel; Oh, Paul I.; Bennett, Steffany A. L.; Lanctôt, Krista L. // Neuropsychiatric Disease & Treatment;Sep2015, Vol. 11, p2309 

    Introduction: Depression is a frequent complication of coronary artery disease (CAD) with an unknown etiology. Platelet activating factor (PAF) lipids, which are associated with CAD, have recently been linked with novel proposed etiopathological mechanisms for depression such as inflammation,...

  • Impact of perioperative acute ischemic stroke on the outcomes of noncardiac and nonvascular surgery: a single centre prospective study. Biteker, Murat; Kayatas, Kadir; Türkmen, Funda Muserref; Mısırlı, Cemile Handan // Canadian Journal of Surgery;Jun2014, Vol. 57 Issue 3, pE55 

    Background: Although ischemic stroke is a well-known complication of cardiovascular surgery it has not been extensively studied in patients undergoing noncardiac surgery. The aim of this study was to assess the predictors and outcomes of perioperative acute ischemic stroke (PAIS) in patients...

  • Depression 3 and 9 months after discharge is less common in cardiac patients who are receiving statins at discharge. Berk, Michael; Krantz, David S. // Evidence Based Mental Health;May2012, Vol. 15 Issue 2, p39 

    The article presents a study on the possible association between the use of statin and a reduced risk of developing depression after being discharged from the hospital in individuals who experienced a cardiac event or intervention. The study found that among patients hospitalised for a cardiac...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics